NEU Application for quotation of securities - NEU 12/03/24 download Created with Sketch. 14.25KB Share NEU 2023 Results webinar 29/02/24 download Created with Sketch. 2.88MB Share NEU Neuren reports profit of $157 million for 2023 29/02/24 PRICE SENSITIVE download Created with Sketch. 928.21KB Share NEU Appendix 4E and 2023 full year accounts 29/02/24 PRICE SENSITIVE download Created with Sketch. 713.93KB Share NEU Neuren 2023 results investor webinar on 29 February 2024 29/02/24 download Created with Sketch. 174.93KB Share NEU DAYBUE net sales US$87.1 million in Q4 2023 28/02/24 PRICE SENSITIVE download Created with Sketch. 451.14KB Share NEU Comment on research report 16/02/24 PRICE SENSITIVE download Created with Sketch. 219.15KB Share NEU Pause in Trading 16/02/24 PRICE SENSITIVE download Created with Sketch. 115.14KB Share NEU Notification regarding unquoted securities - NEU 08/02/24 download Created with Sketch. 17.81KB Share NEU Application for quotation of securities - NEU 01/02/24 download Created with Sketch. 24.82KB Share NEU Q4 2023 Appendix 4C Cash Flow Report 31/01/24 PRICE SENSITIVE download Created with Sketch. 154.86KB Share NEU Q4 2023 quarterly activity report 31/01/24 PRICE SENSITIVE download Created with Sketch. 639.68KB Share NEU Completion of enrolment in Neuren's Angelman P2 trial 20/12/23 PRICE SENSITIVE download Created with Sketch. 205KB Share NEU Application for quotation of securities - NEU 19/12/23 download Created with Sketch. 28.11KB Share NEU Investor presentation, 18 December 2023 18/12/23 PRICE SENSITIVE download Created with Sketch. 2.97MB Share NEU P2 trial shows significant improvements in Phelan-McDermid 18/12/23 PRICE SENSITIVE download Created with Sketch. 723.12KB Share NEU Trading Halt 14/12/23 PRICE SENSITIVE download Created with Sketch. 198.45KB Share NEU Neuren completes enrolment in Pitt Hopkins Phase 2 trial 05/12/23 PRICE SENSITIVE download Created with Sketch. 188.42KB Share NEU Comment on media speculation 20/11/23 download Created with Sketch. 177.19KB Share NEU Neuren completes Phelan-McDermid syndrome Phase 2 trial 13/11/23 download Created with Sketch. 200.25KB Share NEU Investor presentation, 8 November 2023 08/11/23 download Created with Sketch. 2MB Share NEU DAYBUE net sales US$66.9 million in Q3 2023 03/11/23 PRICE SENSITIVE download Created with Sketch. 209.5KB Share NEU Q3 2023 quarterly activity and cash flow report 20/10/23 PRICE SENSITIVE download Created with Sketch. 556.7KB Share NEU Change of Director's Interest Notice - J Basile 14/09/23 download Created with Sketch. 177.21KB Share NEU S&P DJI Announces September 2023 Quarterly Rebalance 01/09/23 PRICE SENSITIVE download Created with Sketch. 121.59KB Share NEU Investor presentation, 28 August 2023 28/08/23 download Created with Sketch. 1.72MB Share NEU Neuren reports 2023 half-year profit after tax of $48m 28/08/23 download Created with Sketch. 393.66KB Share NEU Half Yearly Report and Accounts 28/08/23 PRICE SENSITIVE download Created with Sketch. 485.54KB Share NEU Notification of half-year results & investor web conference 25/08/23 download Created with Sketch. 153.58KB Share NEU Q2 2023 quarterly activity and cash flow report 31/07/23 PRICE SENSITIVE download Created with Sketch. 545.93KB Share NEU Neuren receives US$100m for expanded DAYBUE agreement 27/07/23 PRICE SENSITIVE download Created with Sketch. 162.94KB Share NEU Investor web conference presentation, 14 July 2023 14/07/23 download Created with Sketch. 669.71KB Share NEU Neuren and Acadia expand global partnership for trofinetide 14/07/23 PRICE SENSITIVE download Created with Sketch. 179.35KB Share NEU Neuren completes enrolment in Phelan-McDermid Phase 2 trial 30/06/23 PRICE SENSITIVE download Created with Sketch. 128.16KB Share NEU Neuren opens first site in US for Prader-Willi Phase 2 trial 28/06/23 PRICE SENSITIVE download Created with Sketch. 272.4KB Share NEU Change of Director's Interest Notice 14/06/23 download Created with Sketch. 125.7KB Share NEU Neuren receives US$40m milestone payment 07/06/23 PRICE SENSITIVE download Created with Sketch. 122.47KB Share NEU Neuren presenting at Jefferies Global Healthcare Conference 05/06/23 download Created with Sketch. 120.13KB Share NEU Results of Meeting 30/05/23 download Created with Sketch. 63.25KB Share NEU AGM Chair Address & CEO Presentation 30/05/23 download Created with Sketch. 1.42MB Share NEU Notice of Annual General Meeting/Proxy Form 28/04/23 download Created with Sketch. 320.3KB Share NEU Virtual AGM online guide 28/04/23 download Created with Sketch. 1MB Share NEU Q1 2023 quarterly activity and cash flow report 28/04/23 PRICE SENSITIVE download Created with Sketch. 331.52KB Share NEU Appendix 4G 27/04/23 download Created with Sketch. 149.33KB Share NEU 2022 Annual Report to shareholders 27/04/23 download Created with Sketch. 1.81MB Share NEU DAYBUE (trofinetide) launched in US - Neuren earns US$40m 18/04/23 PRICE SENSITIVE download Created with Sketch. 330.95KB Share NEU Application for quotation of securities - NEU 27/03/23 download Created with Sketch. 24.24KB Share NEU Investor Presentation, 14 March 2023 14/03/23 download Created with Sketch. 1.49MB Share NEU Notification of investor webinar 13/03/23 download Created with Sketch. 155.1KB Share NEU FDA approves Daybue - the first treatment for Rett syndrome 13/03/23 PRICE SENSITIVE download Created with Sketch. 258.83KB Share NEU Initial Director's Interest Notice 02/03/23 download Created with Sketch. 170.86KB Share NEU Neuren appoints Joe Basile to board of directors 02/03/23 download Created with Sketch. 120.39KB Share NEU Investor presentation, 1 March 2023 01/03/23 download Created with Sketch. 1.54MB Share NEU Investor Presentation, 24 February 2023 24/02/23 download Created with Sketch. 1.32MB Share NEU Neuren reports 2022 full-year results 24/02/23 PRICE SENSITIVE download Created with Sketch. 177.83KB Share NEU Appendix 4E and 2022 full year accounts 24/02/23 PRICE SENSITIVE download Created with Sketch. 458.57KB Share NEU Application for quotation of securities - NEU 21/02/23 download Created with Sketch. 24.25KB Share NEU Q4 2022 quarterly activity and cash flow report 31/01/23 PRICE SENSITIVE download Created with Sketch. 278.86KB Share NEU Prader-Willi syndrome IND for NNZ-2591 approved by FDA 23/01/23 PRICE SENSITIVE download Created with Sketch. 149.69KB Share NEU Neuren submits IND & first patients complete Phase 2 trials 23/12/22 PRICE SENSITIVE download Created with Sketch. 285.67KB Share NEU Becoming a substantial holder 07/12/22 download Created with Sketch. 197.83KB Share NEU Ceasing to be a substantial holder 02/12/22 download Created with Sketch. 90.6KB Share NEU Change in substantial holding 23/11/22 download Created with Sketch. 250.67KB Share NEU Jefferies London Healthcare Conference 2022 presentation 18/11/22 download Created with Sketch. 1.25MB Share NEU Q3 2022 quarterly activity and cash flow report 27/10/22 PRICE SENSITIVE download Created with Sketch. 409.29KB Share NEU Neuren receives US$10 million milestone payment 20/10/22 PRICE SENSITIVE download Created with Sketch. 147.13KB Share NEU Investor presentation, 14 September 2022 14/09/22 download Created with Sketch. 1.38MB Share NEU Rett Syndrome NDA accepted for Priority Review by FDA 13/09/22 PRICE SENSITIVE download Created with Sketch. 231.46KB Share NEU S&P DJI Announces September 2022 Quarterly Rebalance 02/09/22 PRICE SENSITIVE download Created with Sketch. 134KB Share NEU Half-year shareholder update 24/08/22 download Created with Sketch. 283.08KB Share NEU Half Yearly Report and Accounts 24/08/22 PRICE SENSITIVE download Created with Sketch. 338.87KB Share NEU Investor presentation, 8 August 2022 08/08/22 download Created with Sketch. 1.18MB Share NEU Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS 08/08/22 PRICE SENSITIVE download Created with Sketch. 178.95KB Share NEU Quarterly Activities/Appendix 4C Cash Flow Report 29/07/22 PRICE SENSITIVE download Created with Sketch. 349.07KB Share NEU Acadia submits Rett Syndrome New Drug Application to the FDA 19/07/22 PRICE SENSITIVE download Created with Sketch. 309.46KB Share NEU Neuren commences Phase 2 trial of NNZ-2591 in Angelman 12/07/22 PRICE SENSITIVE download Created with Sketch. 154.47KB Share NEU Notification regarding unquoted securities - NEU 08/07/22 download Created with Sketch. 27.75KB Share NEU Neuren appoints Chief Medical Officer in United States 08/07/22 PRICE SENSITIVE download Created with Sketch. 150.09KB Share NEU Results of Meeting 30/05/22 download Created with Sketch. 63.57KB Share NEU AGM Chairman's Address & CEO Presentation 30/05/22 download Created with Sketch. 683.09KB Share NEU Quarterly Activities/Appendix 4C Cash Flow Report 29/04/22 PRICE SENSITIVE download Created with Sketch. 276.23KB Share NEU Virtual AGM online guide 28/04/22 download Created with Sketch. 1MB Share NEU Notice of Annual General Meeting/Proxy Form 28/04/22 download Created with Sketch. 781.61KB Share NEU Change in substantial holding 27/04/22 download Created with Sketch. 235.82KB Share NEU Appendix 4G 27/04/22 download Created with Sketch. 146.25KB Share NEU Annual Report to shareholders 27/04/22 download Created with Sketch. 1.72MB Share NEU FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial 25/03/22 PRICE SENSITIVE download Created with Sketch. 151.55KB Share NEU FDA approval for Phelan-McDermid IND and Phase 2 trial 23/03/22 PRICE SENSITIVE download Created with Sketch. 152.68KB Share NEU Ethics approval for Angelman Phase 2 trial in Australia 11/03/22 PRICE SENSITIVE download Created with Sketch. 152.94KB Share NEU S&P DJI Announces March 2022 Quarterly Rebalance 04/03/22 PRICE SENSITIVE download Created with Sketch. 175.5KB Share NEU Investor presentation 25 Feb 2022 25/02/22 download Created with Sketch. 886.27KB Share NEU FDA approval for Angelman IND and Phase 2 trial 25/02/22 PRICE SENSITIVE download Created with Sketch. 154.3KB Share NEU 2021 Results - a transformational year for Neuren 24/02/22 PRICE SENSITIVE download Created with Sketch. 175.8KB Share NEU Preliminary Final Report and 2021 Full Year Accounts 24/02/22 PRICE SENSITIVE download Created with Sketch. 486.79KB Share NEU Notification regarding unquoted securities - NEU 03/02/22 download Created with Sketch. 28.31KB Share NEU Neuren appoints Vice President, Corporate Development 01/02/22 download Created with Sketch. 147.8KB Share NEU Q4 2021 quarterly activity and cash flow report 31/01/22 PRICE SENSITIVE download Created with Sketch. 339.96KB Share NEU Becoming a substantial holder 10/12/21 download Created with Sketch. 200.6KB Share NEU Positive topline results from Phase 3 trial in Rett syndrome 07/12/21 PRICE SENSITIVE download Created with Sketch. 174.6KB Share NEU Neuren presenting at Bell Potter Healthcare Conference 10/11/21 download Created with Sketch. 719.92KB Share